Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.81 |
| ▸ | FLT3 | P36888 | 9/20 | 0.81 |
| ▸ | BLK | P51451 | 8/20 | 0.81 |
| ▸ | BTK | Q06187 | 7/20 | 0.70 |
| ▸ | JAK2 | O60674 | 3/20 | 0.63 |
| ▸ | JAK1 | P23458 | 3/20 | 0.63 |
| ▸ | JAK3 | P52333 | 3/20 | 0.63 |
| ▸ | TYK2 | P29597 | 2/20 | 0.63 |
| ▸ | TTK | P33981 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15752405 | 0.91 | EGFR (0.81) | EGFRFLT3BLKBTKJAK2 | |
| SCHEMBL16680560 | 0.89 | FLT3 (1.00) | EGFRFLT3BLKBTKJAK3 | |
| SCHEMBL15992589 | 0.88 | EGFR (0.85) | EGFRFLT3BLKBTKJAK3 | |
| SCHEMBL15752575 | 0.88 | EGFR (0.78) | EGFRFLT3BLKBTK | |
| SCHEMBL18001831 | 0.87 | BTK (0.78) | EGFRFLT3BLKBTKJAK2 | |
| SCHEMBL15752413 | 0.86 | EGFR (0.67) | EGFRFLT3BLKBTKJAK2 | |
| SCHEMBL15752456 | 0.86 | EGFR (0.67) | EGFRFLT3BLKBTKJAK2 | |
| SCHEMBL15752381 | 0.86 | EGFR (0.81) | EGFRFLT3BLKBTKJAK2 | |
| SCHEMBL18002317 | 0.85 | BTK (0.72) | EGFRFLT3BLKBTKJAK2 | |
| SCHEMBL15752331 | 0.84 | EGFR (0.64) | EGFRFLT3BLKBTKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249131-A1 | Substituted 7-Oxo-Pyrido[2,3-d]Pyrimidines and Methods of Use | AMGEN INC. | 2014-09-04 | — | — | US | disclosed |
| US-20140249131-A1 | Substituted 7-Oxo-Pyrido[2,3-d]Pyrimidines and Methods of Use | AMGEN INC. | 2014-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249131-A1 | Substituted 7-Oxo-Pyrido[2,3-d]Pyrimidines and Methods of Use | DPYD, TYMP, TYMS | EGFR 1611/4885FLT3 262/4885BLK 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.